Drug Database · Clinicians

Naphazoline + Pheniramine

Brands (6) Allerloupe, Decocon A, Irazol…Show all

US brand (reference label): Opcon-A; not a Philippine-registered brand.

Antihistamine/Decongestant PH FDA category
Fixed-dose combination.

Rx · Prescription drug7 PH products
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 2d7cfae7-8af4-4fee-93e1-e5cfe455c5a5, version date March 20, 2026 (Opcon-A · Bausch & Lomb Incorporated). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • Uses temporarily relieves itching and redness caused by pollen, ragweed, grass, animal hair and dander
US FDA label
Full indications and usage US FDA label

Uses temporarily relieves itching and redness caused by pollen, ragweed, grass, animal hair and dander

Dosing: Adult

Dosage and administration (US label) US FDA label

Directions Adults and children 6 years of age and older: Instill 1 or 2 drops in the affected eye(s) up to 4 times daily. Children under 6 years: ask a doctor

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosage forms

Philippines

  • Per ml sterile ophthalmic solution: 2.2 mg/100 mcg, 3 mg/250 mcg
  • Ml ophthalmic solution: 3 mg/250 mcg
  • Per ml: 3 mg/250 mcg

Registered products in the Philippines

7 products registered with the Food and Drug Administration (FDA) Philippines list Naphazoline + Pheniramine as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products7
Philippine FDA-registered products for Naphazoline + Pheniramine
Package insert
AllerloupePheniramine Maleate + Naphazoline Hydrochloride
3 mg/ 250 mcg per mL Sterile Ophthalmic SolutionPlastic Squeeze White Bottle x 10 mL (Box of 1's)
Rx
Ashford Pharmaceutical Laboratories, Inc.Philippines
PNJ Pharma EnterpriseTrader: Medilife Pharma, Inc.
DRP-623-04
Oct 9, 2027
Decocon APheniramine Maleate + Naphazoline Hydrochloride
3 mg/250 mcg per mL Sterile Ophthalmic Solution (Eye Drops)10 mL LDPE dropper container (Box of 1's)
Rx
ASHFORD PHARMACEUTICAL LABORATORIES, INC.Philippines
Trader: SENSOMED PHILS., INC.
DR-XY16681
Feb 13, 2029
IrazolPheniramine Maleate + Naphazoline Hydrochloride
3 mg/250 mcg per mL Sterile Ophthalmic SolutionPlastic Squeeze White Bottle x 10 mL (Box of 1's)
Rx
Ashford Pharmaceutical Laboratories, Inc.Philippines
Trader: Medilife Pharma, Inc.
DRP-623
Oct 9, 2027
Naphcon-APheniramine Maleate/ Naphazoline Hydrochloride
3 mg/ 250 mcg/ mL Ophthalmic SolutionPlastic Droptainer Dispenser x 15 mL (Box of 1's)
Rx
Alcon Singapore Manufacturing Pte. Ltd.Singapore
Importer: Alcon Laboratories (Phils.), Inc.
DR-XY4858
Sep 1, 2027
NonePheniramine (as Maleate) + Naphazoline Hydrochloride
2.2 mg/100 mcg per mL (0.22% w/v / 0.01% w/v) Sterile Ophthalmic Solution10 mL White LDPE Bottle, dropper plug, and tamper evident cap in a box
Rx
EL Laboratories, Inc.Philippines
Trader: Celsus Pharmaceuticals Phils., Inc.
DR-XY40553
Jan 19, 2027
PhenazolPheniramine Maleate + Naphazoline Hydrochloride
Ophthalmic Solution and 3 mg/250 mcg per mLLDPE Plastic Dropper-Tipped Bottle x 10 mL (Box of 1's); LDPE Plastic Dropper-Tipped Bottle x 2.5 mL (Physician Sample) (Box of 1's)
Rx
Ashford Pharmaceutical Laboratories, Inc.Philippines
Trader: Vendiz Pharmaceuticals Inc.
DRP-12782
Nov 12, 2029
VistallergPheniramine Maleate + Naphazoline Hydrochloride
3 mg/250 mcg per mL (0.3% w/v/0.025% w/v) Sterile Ophthalmic Solution (Drops)10 mL HDPE pilfer-guard eyedropper plastic container in a box
Rx
EL Laboratories, Inc.Philippines
Trader: Vista Pharma, Inc.
DR-XY27526
Apr 20, 2027

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Warnings/Precautions

Warnings and precautions (US label) US FDA label

Warnings For external use only Do not use if you are sensitive to any ingredient in this product if solution changes color or becomes cloudy Ask a doctor before use if you have heart disease high blood pressure trouble urinating due to an enlarged prostate gland narrow angle glaucoma When using this product overuse may cause more eye redness pupils may become enlarged temporarily do not touch tip of container to any surface to avoid contamination you may feel a brief tingling after putting drops in eye replace cap after use remove contact lenses before using Stop use and ask a doctor if you experience eye pain changes in vision redness or irritation of the eye that worsens or lasts more than 72 hours Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.

Accidental oral ingestion in infants and children may lead to coma and marked reduction in body temperature.

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Opcon-A · Bausch & Lomb Incorporated [US FDA-approved label, version 2, March 20, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d7cfae7-8af4-4fee-93e1-e5cfe455c5a5
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .